Recent Thinking from AcceleromicsHealth
Our team draws on hands-on experience guiding health technology companies and on active medical practice. In these concise briefings we capture the questions founders, product leaders, and investors raise most frequently.
Does your software count as a medical device? Settle it early.
Product classification is one of the most consequential calls a digital health company makes. Whether your software is regulated as a medical device shapes your evidence requirements, your development workflow, your launch timeline, and often the marketing claims you may legally make. Even so, many teams postpone the question until the product and its claims are already fixed. We advise founders to document intended use and indications for use before writing the first line of production code. Then map the product against the relevant frameworks — including FDA guidance on Software as a Medical Device and clinical decision support, plus the risk categorisation approaches used in the UK, the EU, and Asia-Pacific markets. Choosing deliberately between a narrower, lower-risk claim now and a broader claim later can save a year or more.
Clinical validation that clinicians and payers will trust
A retrospective accuracy study is seldom sufficient. Health systems want proof that your product improves outcomes, saves clinician time, or lowers cost in settings comparable to theirs. Payers expect the same evidence framed in economic terms. Building studies that answer those questions from the outset costs far less than running them again. A strong validation plan specifies a clinically meaningful endpoint, a realistic comparator, and a population that mirrors the patients who will actually use the product. It also anticipates subgroup performance and generalisability — now standard questions for any algorithm-driven tool.
Build reimbursement into the product, not just the sales plan
If no one gets paid when your product is used, adoption rests entirely on goodwill. Reimbursement strategy belongs on the product roadmap, not only in the sales plan. Existing billing codes for remote monitoring, telehealth, and care management may already cover part of your value proposition — as long as your workflow and documentation are designed to support them. Where no pathway exists yet, value-based contracts, employer and health plan partnerships, and health system licensing can bridge the gap while you build the evidence needed for broader coverage.
Cross-border privacy: plan for more than one market
Health data ranks among the most heavily regulated data in the world. A product designed only around HIPAA may need substantial rework to launch under GDPR in Europe or under data protection laws in South Korea and elsewhere in Asia. Choices about data residency, consent, de-identification, and vendor agreements are much easier to make once, at the architecture stage. A privacy and security posture that meets the strictest market you plan to enter also becomes a commercial asset, shortening procurement reviews with hospitals and enterprise customers.
Design for the clinical workflow, not around it
Even the highest-performing tool will fail if it adds clicks, alerts, or logins to an already overloaded clinical day. Before building, spend time observing the people who will use your product. Understand who acts on its output, when, and what they stop doing as a result. Interoperability matters too. Standards such as HL7 FHIR and integration with the electronic health record are increasingly table stakes for enterprise buyers. Planning for them